CE Mark vs FDA 510(k): EU MDR and US Regulatory Pathway Comparison
- 1 day ago
- 19 min read
CE Mark and FDA 510(k) are separate regulatory pathways for medical device market access. CE Mark certification demonstrates compliance with the European Union Medical Device Regulation (EU MDR 2017/745), granting sales rights across 30 European Economic Area countries. FDA 510(k) clearance proves substantial equivalence to predicate devices under US regulations, enabling United States market access only. Key differences: CE Mark requires Notified Body certification for Class IIa+ devices and clinical evaluation for all devices; FDA 510(k) requires predicate device comparison with clinical data needed in only ~15% of submissions.
This comprehensive guide compares EU MDR requirements for CE Mark certification versus FDA 510(k) clearance requirements across every dimension that matters to manufacturers: regulatory philosophy, device classification, clinical evidence expectations, quality systems, timelines, costs, and strategic sequencing.
What Are You Actually Comparing? CE Mark vs FDA 510(k) Fundamentals
Before diving into detailed comparisons, it’s essential to understand what CE marking and FDA 510(k) actually represent, because they are fundamentally different regulatory concepts.
CE Mark: Conformity-Based Market Access
CE marking is the conformity mark that manufacturers affix to a medical device after completing the applicable conformity assessment under the European Union Medical Device Regulation, EU MDR 2017/745. In practical terms:
EU MDR 2017/745 = the regulation
CE mark = the marking that indicates conformity with the regulation’s applicable requirements
What CE marking grants: access to place compliant devices on the EU and EEA market, including:
All 27 European Union member states
Iceland, Liechtenstein, and Norway
Switzerland should be treated separately in medical device strategy, because the EU-Switzerland regulatory position for medical devices changed after the MDR and should not be grouped casually with the EU/EEA.
Regulatory authority: Notified Bodies, which are organizations designated by EU Member States, are involved for all Class IIa, IIb, and III devices, as well as some specific Class I devices. Many Class I devices can still be self-certified by the manufacturer.
Core requirement: Devices must meet the General Safety and Performance Requirements, GSPRs, in Annex I of the MDR. Conformity is demonstrated through the applicable conformity assessment route, including Annex IX, X, or XI, depending on device classification and pathway.
FDA 510(k): Equivalence-Based U.S. Market Access
FDA 510(k) is a premarket notification submitted to the U.S. Food and Drug Administration to demonstrate that a medical device is substantially equivalent to a legally marketed predicate device. The name comes from section 510(k) of the Federal Food, Drug, and Cosmetic Act.
What 510(k) clearance grants: authorization to market the device in the United States. Unlike CE marking, 510(k) is a U.S.-specific pathway.
Regulatory authority: Most 510(k) submissions are reviewed through FDA, but some eligible devices may use FDA’s Third Party Review Program, where an FDA-recognized review organization performs the primary review and FDA makes the final decision.
Core requirement: Manufacturers must show that their device is substantially equivalent to a predicate device in intended use and technological characteristics, supported by performance data where needed.
The Fundamental Difference
EU MDR / CE mark: “Show that your device conforms to applicable safety and performance requirements.”
Conformity-based, risk-classified regulation
Compliance with General Safety and Performance Requirements
Clinical evaluation and technical documentation support conformity assessment
FDA 510(k): “Show that your device is substantially equivalent to a legally marketed predicate.”
Equivalence-based regulation
Comparison to a predicate device already legally marketed in the U.S.
Intended use, technological characteristics, and performance evidence drive the review
This difference shapes everything downstream, from evidence strategy to testing to documentation structure. For many teams, that is where the real work begins. It is also where regulatory work often slows down. The issue is not usually lack of guidance, it is figuring out the right product code, predicate set, standards, and evidence plan early enough to avoid rework later. This is exactly where Complizen fits, helping teams surface likely product codes, predicates, FDA sources, and standards in one place before they commit to the wrong path.
At-a-Glance Comparison: CE Mark (EU MDR) vs FDA 510(k)
Factor | CE Mark (EU MDR 2017/745) | FDA 510(k) |
Market Access | EU and EEA market, 30 states | United States primary market access, sometimes used as a reference internationally |
Regulatory Authority | Notified Bodies for many devices, with oversight by national competent authorities | FDA, primarily through CDRH |
Regulatory Philosophy | Conformity-based, risk-classified regulation focused on compliance with safety and performance requirements | Equivalence-based regulation focused on substantial equivalence to a predicate device |
Device Classification | Class I, IIa, IIb, III | Class I, II, III |
Core Requirement | Compliance with EU MDR General Safety and Performance Requirements, including Annex I | Substantial equivalence to a legally marketed predicate device |
Clinical Evidence | Clinical evaluation required under MDR for all devices, with scope depending on risk and evidence needs | Clinical data required in a minority of 510(k)s |
Quality System | A compliant QMS is expected under MDR, with ISO 13485 commonly used in practice | 21 CFR Part 820, now revised into the QMSR and more closely aligned with ISO 13485 |
Third-Party Assessment | Notified body involvement for Class IIa, IIb, III, and some Class I devices | Most submissions are reviewed by FDA directly, though some eligible devices may use the Third Party Review Program |
Timeline | Varies widely based on class, documentation quality, and notified body capacity | FDA review goals are shorter than real-world total time to decision, which often extends due to holds and information requests |
Cost Range | Total cost varies widely depending on testing, technical documentation, and notified body scope | Total cost varies widely depending on testing, preparation, consultants, and FDA fees |
Validity Period | Certificates are issued for a defined period, up to five years, and may be renewed | No fixed expiry, but significant changes may require a new 510(k) |
Annual Fees | Authorized representative and ongoing compliance costs vary by arrangement | Annual establishment registration fee applies and changes each fiscal year |
Post-Market | PMS, PMCF where applicable, vigilance, and notified body surveillance | Medical Device Reporting, annual registration, and FDA inspections as applicable |
Clinical Trial Expectations | More likely for higher-risk and novel devices, depending on available evidence | Less common, especially where strong predicates and non-clinical testing are sufficient |
Global Use | Primarily for EU/EEA access, with separate country-by-country relevance outside Europe | U.S.-specific pathway |
How Do Device Classification Systems Compare?
Device classification drives regulatory requirements, evidence expectations, timelines, and cost. The EU MDR and FDA use different classification systems, so the same device can follow a different regulatory path in Europe and the United States.
EU MDR Classification (Annex VIII Rules)
EU MDR classifies devices using the classification rules in Annex VIII, based on factors such as:
Duration of body contact, transient, short-term, or long-term
Degree of invasiveness, non-invasive, invasive, or implantable
Whether the device is active
The anatomical site or physiological system involved
Specific risk features, such as sterility, measuring function, reuse, or absorption by the body
Four risk classes:
Class I, lowest risk
Non-invasive or low-risk devices. Many basic Class I devices can be self-certified by the manufacturer.
Examples may include basic bandages, some wheelchairs, and other low-risk non-invasive devices.
Subclasses with additional oversight include:
Class Is: sterile Class I devices
Class Im: Class I devices with a measuring function
Class Ir: reusable surgical instruments
Class IIa, lower-medium risk
Devices with higher risk than Class I and typically requiring notified body involvement.
Examples can include some hearing aids, contact lenses, and certain dental materials. Clinical evidence expectations are higher than for Class I, but depend on the device and claims.
Class IIb, medium-high risk
Devices with more significant interaction with the body or higher risk profiles.
Examples can include ventilators, insulin pumps, and some long-term surgically invasive devices. Evidence expectations are typically more demanding than for Class IIa.
Class III, highest risk
High-risk implantable, life-supporting, or life-sustaining devices.
Examples can include heart valves, pacemakers, and certain breast implants. These devices often require robust clinical evidence, and in many cases clinical investigation data.
FDA Classification (Class + Product Code-Based)
FDA classifies devices based on intended use and indications for use, then places them into an existing regulatory classification and associated product code.
Class I, lowest risk
Minimal potential for harm.
Examples may include elastic bandages, some manual wheelchairs, and other low-risk devices. Most Class I devices are exempt from 510(k), subject to limitations.
Class II, moderate risk
Moderate-risk devices that often require special controls.
Examples may include powered wheelchairs, infusion pumps, surgical drapes, and many contact lenses. Most devices reviewed through the 510(k) pathway are Class II.
Class III, highest risk
Devices that support or sustain human life, are implanted, or present potentially unreasonable risk.
Examples include many heart valves and implantable pacemakers. These devices typically require PMA rather than 510(k), although some legacy Class III devices still use 510(k).
Critical Difference: The Same Device Can Fall Into Different Classes
The same medical device can fall into different classifications under EU MDR and FDA, which can change the pathway, evidence burden, and review mechanics.
Example 1: Contact lenses
EU MDR: often Class IIa
FDA: can be Class II or Class III, depending on the lens type and intended use
Example 2: Surgical sutures
EU MDR: classification can vary depending on invasiveness, duration, absorbability, and material characteristics
FDA: many surgical sutures are regulated as Class II devices
This is why manufacturers need to classify a device under both systems independently. You cannot assume that an EU classification maps neatly to an FDA class, or vice versa. For teams building a submission strategy, classification is the first place where a lot of downstream work gets locked in, predicate strategy, testing, clinical evidence, and even which standards matter most. That is also where Complizen becomes useful, because once the likely product code, predicate set, recalls, and standards are visible early, teams can avoid building the wrong regulatory path.
What’s the Core Regulatory Philosophy Difference?
The biggest difference between CE marking and FDA 510(k) is not just paperwork, it is the underlying regulatory logic. The two systems ask different core questions, and that changes how manufacturers build evidence, choose tests, and plan their pathway.
EU MDR: Conformity-Based Regulation
Core question: Does this device conform to the applicable safety and performance requirements for its intended purpose?
Under EU MDR, manufacturers must demonstrate that the device:
Meets the General Safety and Performance Requirements (GSPRs) in Annex I
Supports conformity through clinical evaluation under Article 61 and Annex XIV, as applicable
Has an acceptable benefit-risk profile
Is safe and performs as intended when used according to its intended purpose
In practice, that means the manufacturer must show:
The device performs as intended
The expected benefits outweigh the risks for the target population
The technical documentation supports conformity with the applicable requirements
Use of relevant harmonised standards can create a presumption of conformity when those standards are cited in the Official Journal of the European Union
There is no FDA-style predicate requirement under EU MDR. You do not need to prove that your device matches something already on the market. You need to show that your own device conforms to the applicable safety and performance requirements and has an acceptable benefit-risk profile.
FDA 510(k): Equivalence-Based Regulation
Core question: Is this device substantially equivalent to a legally marketed predicate device?
Under the FDA 510(k) pathway, manufacturers must demonstrate substantial equivalence by showing:
u
The device has the same intended use as the predicate
It has the same technological characteristics, or different technological characteristics that do not raise different questions of safety and effectiveness
The supporting performance data are sufficient for FDA to find the device as safe and effective as the predicate
In practice, that means the manufacturer must show:
A suitable legally marketed predicate device exists
The intended use aligns with that predicate
The technology is the same, or acceptably different
The testing package is strong enough to support substantial equivalence
This is why predicate strategy matters so much in 510(k) planning. For many teams, one of the hardest parts is not writing the submission, it is identifying the right product code, finding the right predicate set, and linking that to the right tests, standards, and risk story early. That is also where a source-linked workspace can be genuinely useful, because it reduces the chance of building the wrong argument around the wrong comparison set.
What This Means in Practice
For novel devices:
For devices that are similar to existing products:
EU MDR: the manufacturer must still demonstrate conformity with the applicable GSPRs
FDA 510(k): an appropriate predicate can make the pathway more straightforward, especially when non-clinical testing is enough to support substantial equivalence
For clinical evidence expectations:
EU MDR: clinical evaluation is required, and in some cases literature and existing clinical data may support parts of the assessment, depending on the device and claims
FDA 510(k): clinical data are required in a minority of submissions, typically when bench, software, biocompatibility, or other non-clinical testing is not enough to support substantial equivalence
Clinical Evidence Requirements: One of the Biggest Differences
Clinical evidence is one of the biggest practical differences between the CE marking and FDA 510(k) pathways. The gap is not that one system cares about evidence and the other does not. It is that they ask for evidence in different ways and for different regulatory purposes.
EU MDR Clinical Evidence Requirements
Under EU MDR, clinical evaluation is required for medical devices across classes under Article 61 and Annex XIV. Clinical evaluation is the documented process of assessing relevant clinical data to support conformity with applicable safety and performance requirements and to confirm an acceptable benefit-risk profile.
For devices under MDR, manufacturers generally need to:
Plan and document a clinical evaluation
Assess relevant clinical data, which may include published literature, clinical investigation data, post-market data, and PMCF where applicable
Support the applicable General Safety and Performance Requirements that require clinical evidence
Show that the device performs as intended and that benefits outweigh risks
Common clinical data sources can include:
Published literature, where relevant and methodologically sound
Clinical investigations, where existing data are insufficient
Equivalent device data, but only where equivalence can be properly demonstrated under MDR
Post-market clinical follow-up (PMCF) and other post-market sources
A Clinical Evaluation Report (CER) is still a standard deliverable in practice. MEDDEV 2.7/1 Rev. 4 remains a commonly referenced methodology, but MDR and MDCG guidance take precedence wherever there is any conflict.
The important point is this: even when a new prospective clinical study is not required, clinical evaluation is still mandatory under MDR. That is why EU clinical evidence work often feels heavier than many teams expect. It is also why early evidence mapping matters, especially when you are trying to understand which claims, standards, risks, and data gaps will drive the burden later.
FDA 510(k) Clinical Evidence Requirements
Under the FDA 510(k) pathway, clinical data are required in only a minority of submissions. FDA’s 510(k) program guidance says the agency requests clinical data for less than 10 percent of 510(k) submissions, and FDA’s IDE page similarly states that only a small percentage of 510(k)s require clinical data.
In many 510(k)s, substantial equivalence can be supported through non-clinical evidence such as:
Bench and performance testing
Biocompatibility testing
Software verification and validation
Electrical safety and EMC testing
Sterilization validation
Shelf-life testing
Predicate comparison testing where relevant
FDA may expect clinical data when non-clinical testing is not enough to support substantial equivalence, especially for devices with claims, technological differences, or use scenarios that create unresolved questions of safety or effectiveness. FDA’s 2023 draft guidance was published specifically to clarify these situations.
That difference changes execution. In a 510(k), the real work is often figuring out whether a strong predicate and testing package can carry the argument without clinical data. That is one reason predicate strategy matters so much. If you start with the wrong product code, the wrong comparison set, or the wrong standards, you can end up creating evidence work you did not need.
Bottom line
The cleanest way to say it is this:
EU MDR: clinical evaluation is mandatory, even if literature and existing data are enough
FDA 510(k): clinical data are required only in a minority of cases, when non-clinical evidence is not enough to support substantial equivalence
Quality Management System Requirements
Both pathways require a compliant quality system, but they do not enforce it in the same way. That difference matters because it changes when manufacturers are audited, how conformity is assessed, and how much of the QMS burden shows up before market entry versus after.
EU MDR Quality System Requirements
Under EU MDR Article 10(9), manufacturers must establish, document, implement, maintain, update, and continuously improve a quality management system that supports compliance with the Regulation. In practice, EN ISO 13485:2016 is widely used to structure that system, and it is one of the harmonised standards that can support presumption of conformity for the requirements it covers.
Key QMS elements typically include:
Risk management integrated across the product lifecycle
Design and development controls
Supplier and purchasing controls
Production and process controls
Post-market surveillance processes
Corrective and preventive action processes
Internal audits and management review
For devices that require notified body involvement, the conformity assessment process includes third-party review of the manufacturer’s QMS and related processes. That oversight includes initial assessment and ongoing surveillance, with greater scrutiny for higher-risk devices.
In practice, this means CE-marking work is not just about technical documentation. The QMS, risk files, clinical processes, supplier controls, and post-market systems all need to stand up together. That is one reason EU projects often feel heavier operationally than a simple checklist suggests.
FDA Quality System Requirements
As of February 2, 2026, FDA’s Quality Management System Regulation, QMSR, became effective and amended 21 CFR Part 820 by incorporating ISO 13485:2016 by reference. FDA says this aligns U.S. device QMS requirements more closely with internationally recognized standards while preserving U.S. statutory and regulatory controls where they differ.
Key FDA QMS areas still include:
Design and development controls
Purchasing controls
Production and process controls
CAPA
Complaint handling
Medical Device Reporting obligations where applicable
Servicing controls where applicable
The critical operational difference is this: FDA does not typically audit the QMS as part of 510(k) review before clearance. Manufacturers are still expected to comply, but FDA inspections are scheduled separately using a risk-based approach. FDA also states that ISO 13485 certificates do not replace FDA inspections and do not by themselves prove compliance with QMSR.
What the 2026 QMSR change really means
The QMSR shift is a meaningful harmonization step, especially for companies targeting both Europe and the United States. It can reduce duplicated documentation work and make it easier to build one integrated quality system architecture. But it does not eliminate jurisdiction-specific obligations. FDA still applies U.S. law where it conflicts with ISO 13485, and EU MDR still requires MDR-specific conformity assessment and notified body oversight where applicable.
For dual-market manufacturers, the practical win is not “one certificate solves everything.” The win is building a QMS structure that can support both pathways without duplicating core controls. That is also where connected regulatory work helps. If your design history, supplier controls, complaints, post-market signals, standards, and submission evidence all live in disconnected systems, the QMS burden compounds fast. If they are organized in one traceable workflow, it becomes much easier to see what is missing before an auditor or reviewer finds it first.
Which Pathway Should You Pursue First?
The “CE mark or FDA first?” decision is usually not a legal question alone. It is a business and execution question. The right answer depends on your target market, whether a suitable FDA predicate exists, how much clinical evidence your device is likely to need, and whether your team can support one pathway or two at the same time.
Pursue CE Mark First If:
✅ Europe is your near-term commercial priority
If your early customers, distributors, or launch plans are centered in Europe, CE marking may align better with your first commercial milestone. It also opens access to the EU and EEA market rather than a single country. Europe’s medtech market is the world’s second largest after the United States.
✅ Your device does not have a strong FDA predicate
If there is no suitable legally marketed predicate, the 510(k) pathway may not be available. In that situation, a CE-first strategy may be worth considering, especially if you want to build device-specific evidence before pursuing a U.S. pathway. On the FDA side, the alternative may be De Novo or, for higher-risk products, PMA.
✅ You want to build an evidence base before U.S. entry
Data generated outside the U.S. can sometimes support a later FDA submission, but only if the evidence is relevant and acceptable to FDA. That makes evidence planning important from day one.
✅ You want a broader regional launch before entering the U.S.
CE marking can support access across the EU and EEA, which may fit companies that want a multi-country regional rollout before investing in the U.S. market. That said, broader geographic access does not automatically mean faster revenue, because reimbursement, distribution, procurement, and local execution still matter.
Pursue FDA 510(k) First If:
✅ The U.S. is your primary target market
If your commercial focus is the United States, FDA-first is often the cleanest strategic choice. The U.S. remains the largest medical device market in the world.
✅ You have a strong, recent, and relevant predicate
A clear predicate can make 510(k) strategy much more straightforward. It can reduce the evidence burden and lower the chance that FDA will ask for clinical data, assuming your intended use, technology, and test package line up well. FDA says clinical data are requested in less than 10 percent of 510(k) submissions.
✅ You can support substantial equivalence with non-clinical testing
If bench, software, biocompatibility, electrical safety, sterilization, and related testing are likely to be enough, FDA-first can become more attractive because the pathway may avoid the heavier clinical-evaluation burden that MDR imposes on all devices.
✅ FDA clearance supports your broader regulatory strategy
FDA clearance is U.S.-specific, but some jurisdictions may consider it within reliance-based or abridged regulatory pathways. It does not create automatic market access outside the U.S., but it can still matter strategically.
Consider a Parallel Strategy If:
✅ You have the resources to run two regulatory programs at once
A parallel strategy can make sense when the device is a good fit for both systems, the company has enough operational capacity, and there is a real reason to target both markets in the same window.
✅ Your core technical work can be reused across both pathways
Some testing, technical documentation, and QMS work can be leveraged across both Europe and the U.S., especially now that FDA’s QMSR is more closely aligned with ISO 13485. But the overlap is never perfect, and jurisdiction-specific requirements still need to be managed.
✅ You already understand both your EU classification and FDA predicate strategy
Parallel only works well when the regulatory path is already reasonably clear on both sides. If either classification or predicate strategy is fuzzy, running both at once can multiply confusion instead of reducing time.
That is also where teams often get into trouble. They try to answer “which pathway first?” before they have mapped the actual device classification, likely product code, predicate set, testing package, and evidence burden. In practice, that sequencing matters more than generic advice. This is also where a source-linked workflow can add real value, because once codes, predicates, standards, recalls, and prior evidence are visible in one place, the path usually gets clearer faster.
Can You Leverage One Certification for the Other?
Manufacturers pursuing both Europe and the United States usually ask the same question: if we complete one pathway first, how much of that work can we reuse for the second?
The honest answer is: some underlying data and documentation can carry over, but CE marking and FDA 510(k) are still separate regulatory processes with separate review logic.
Using CE Mark Work to Support an FDA 510(k)
✅ What can often be reused or adapted
Quality system documentation
A QMS built around ISO 13485:2016 is highly relevant after FDA’s QMSR took effect on February 2, 2026, because FDA now incorporates ISO 13485 by reference. But an ISO 13485 certificate does not by itself prove FDA compliance, and it does not replace FDA inspection.
Performance and standards-based testing
Testing performed to internationally recognized standards may often be reusable or adaptable across both pathways, especially in areas like:
Biocompatibility, such as ISO 10993-based testing
Electrical safety and EMC, such as IEC 60601-based testing
Sterilization validation, where FDA recognizes many relevant ISO and AAMI/ISO standards
Core technical documentation
Device description, design and development records, risk management documentation, and parts of the technical evidence package often overlap, even though the final submission structure still needs to be tailored to FDA’s substantial-equivalence framework.
Clinical data generated outside the U.S.
FDA may accept foreign clinical data if the study complies with good clinical practice and the data are relevant to the U.S. population and practice of medicine. That means EU-generated clinical evidence can sometimes support a later FDA submission, but only if it is designed and documented appropriately.
❌ What does not transfer directly
The CE mark itself
CE marking does not substitute for FDA clearance. A manufacturer still has to demonstrate substantial equivalence to a legally marketed U.S. predicate if pursuing 510(k).
The Clinical Evaluation Report as-is
An MDR CER is built to support conformity with EU safety and performance requirements. FDA’s 510(k) review is built around predicate comparison and substantial equivalence. Some underlying data may be reusable, but the argument usually needs to be reframed.
Notified body review
There is no reciprocal recognition that turns notified body review into FDA clearance. FDA still conducts its own review under its own legal framework.
Using FDA 510(k) Work to Support CE Marking
✅ What can often be reused or adapted
Quality documentation
A QMS built for FDA’s QMSR can support a dual-market strategy because it is now more closely aligned with ISO 13485. But EU MDR still has device- and conformity-assessment-specific expectations that go beyond simply having a U.S.-compliant QMS.
Performance testing
Bench, biocompatibility, electrical safety, sterilization, and other recognized-standard testing may often be leveraged across both pathways, provided the testing scope matches the claims and requirements for each market.
Clinical data
U.S. clinical data may support EU clinical evaluation if the evidence is relevant, robust, and suitable for MDR expectations.
❌ What does not transfer directly
FDA 510(k) clearance itself
FDA clearance does not automatically satisfy EU MDR. A manufacturer still has to demonstrate conformity with MDR and prepare the required Annex II and Annex III technical documentation.
Predicate-based logic
EU MDR does not use the FDA-style predicate pathway. Even where equivalence may come up in MDR clinical evaluation, it is not the same regulatory mechanism as a 510(k) predicate comparison.
The 510(k) document package itself
A 510(k) is not a substitute for the MDR technical file. MDR requires its own technical documentation structure and clinical evaluation approach.
Practical strategy for dual-market teams
The best way to think about this is not “Which certificate transfers?” but “Which underlying work product can be designed once and reused well?”
That usually means:
Build a QMS architecture that can support both jurisdictions
Use recognized standards where possible
Plan testing and clinical evidence with both regulators in mind
Expect the submission logic to remain different even when the source data overlap
Bottom line
One certification does not automatically unlock the other. But the underlying QMS work, testing, technical documentation, and some clinical evidence may often be reused or adapted, sometimes significantly, if they were planned properly from the beginning. The certificate itself matters less than the quality and structure of the work behind it.
The Fastest Path to Market
No more guesswork. Move from research to a defendable FDA strategy, faster. Backed by FDA sources. Teams report 12 hours saved weekly.
FDA Product Code Finder, find your code in minutes.
510(k) Predicate Intelligence, see likely predicates with 510(k) links.
Risk and Recalls, scan MAUDE and recall patterns.
FDA Tests and Standards, map required tests from your code.
Regulatory Strategy Workspace, pull it into a defendable plan.
👉 Start free at complizen.ai
Frequently Asked Questions
Can I sell in Europe with only FDA 510(k) clearance?
No. FDA 510(k) clearance supports marketing in the United States, not the EU/EEA. To market a device in Europe, you generally need to meet EU MDR requirements and complete the applicable conformity assessment for CE marking.
Can I sell in the U.S. with only CE marking?
No. CE marking does not replace U.S. device authorization. To market a device in the United States, you typically need the applicable FDA pathway, such as 510(k), De Novo, or PMA, depending on the device.
Which is faster, CE marking or FDA 510(k)?
There is no universal winner. FDA 510(k) can be faster when there is a strong predicate and non-clinical testing is enough. CE marking can move efficiently for some lower-risk devices, but timelines depend heavily on device class, evidence burden, and notified body availability.
Which has stricter clinical evidence requirements?
Usually EU MDR. Clinical evaluation is required under MDR across device classes, while FDA says clinical data are requested in less than 10 percent of 510(k) submissions.
Can the same testing or clinical data support both pathways?
Often, yes, at least in part. Standards-based testing, risk documentation, and some clinical data may be reusable or adaptable across both markets. But the submission logic is different, so the evidence usually has to be framed differently for each regulator.
Can I use a CE-marked device as my FDA predicate?
Not by itself. For a 510(k), FDA requires comparison to a legally marketed U.S. predicate device, not simply a CE-marked product.
How long does each authorization remain valid?
A CE certificate is issued for a defined period and generally may not exceed five years, though it can be renewed. A 510(k) clearance does not have a fixed expiration date, but significant device changes may trigger the need for a new submission.
Do I need both CE marking and FDA clearance for global sales?
Usually, yes, if you want both Europe and the U.S. CE marking covers the EU/EEA market, while FDA 510(k) covers the U.S. Other major markets, like Canada, Japan, Australia, China, and Brazil, have their own regulatory pathways.
